Aptose Biosciences furnishes Reg FD press release

Aptose Biosciences Inc. filed a current report to furnish a company press release under Regulation FD.

Accepted by SEC EDGAR 11/19/2025 - 06:02 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Aptose Biosciences Inc. filed a current report to furnish a company press release under Regulation FD. The filing states that a press release dated November 19, 2025 is attached as Exhibit 99.1 and is incorporated by reference, but is treated as “furnished” rather than “filed” for liability purposes.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aptose Biosciences Inc. (APTOF) disclose in this 8-K?

Aptose Biosciences furnished a press release under Regulation FD. The company attached the November 19, 2025 press release as Exhibit 99.1, making it publicly available while specifying it is furnished, not filed, for Exchange Act liability purposes.

What is Exhibit 99.1 in the Aptose Biosciences (APTOF) 8-K filing?

Exhibit 99.1 is a press release dated November 19, 2025. The company furnished this press release under Regulation FD and incorporated it by reference, while clarifying that it does not count as a filed document under Section 18 of the Exchange Act.

How did Aptose Biosciences (APTOF) classify the attached press release legally?

Aptose Biosciences classified the press release as furnished, not filed. The filing cites General Instruction B.2, meaning the Exhibit 99.1 press release is not subject to Section 18 liability and is only incorporated by reference when specifically cited elsewhere.

Which items of Form 8-K does the Aptose Biosciences (APTOF) report address?

The report addresses Item 7.01, Regulation FD Disclosure, and Item 9.01, Financial Statements and Exhibits. Under Item 9.01, the company lists Exhibit 99.1 as the press release and Exhibit 104 as the cover page interactive data file.

Who signed the Aptose Biosciences (APTOF) 8-K and in what capacity?

The 8-K was signed by William G. Rice, Ph.D. He signed on behalf of Aptose Biosciences Inc. in his roles as Chairman, President, and Chief Executive Officer, consistent with Exchange Act signature requirements for authorized officers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

False000088236100008823612025-11-192025-11-19iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  November 19, 2025

_______________________________

Aptose Biosciences Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Canada	001-32001	98-1136802
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

66 Wellington Street West, Suite 5300

TD Bank Tower, Box 48

Toronto, Ontario M5K 1E6
Canada

(Address of Principal Executive Offices) (Zip Code)

(647) 479-9828

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On November 19, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release dated November 19, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aptose Biosciences Inc.
Date: November 19, 2025	By:	/s/ William G. Rice, Ph.D.
		William G. Rice, Ph.D.
		Chairman, President, and Chief Executive Officer